Profile - To The Moon

angliz

Posts · 179Posts · 179
Following · 0Following · 0
Followers · 0Followers · 0

- anglizangliz
  ·2022-06-07
  Go go go!
  Some Hot Chinese ADRs Gained in Morning Trading
  Some Hot Chinese ADRs Gained in Morning Trading.Alibaba, Pinduoduo, iQIYI, DiDi Global, Baidu, JD.co
  Some Hot Chinese ADRs Gained in Morning Trading
  2.97K Comment
  5
  Share
  Report
- anglizangliz
  ·2022-06-04
  $THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$Just bought abit of this share today! Huat ah!
  2.73K Comment
  4
  Share
  Report
- anglizangliz
  ·2022-01-28
  Wowed
  Apple's Q1 Results A 'Major Statement Of iPhone/Services Demand': Analyst
  Apple, Inc. reported late Thursday with strong quarterly results that "wowed" a Wedbush analyst.The
  Apple's Q1 Results A 'Major Statement Of iPhone/Services Demand': Analyst
  2.50K Comment
  4
  Share
  Report
- anglizangliz
  ·2022-01-21
  Horray!
  Hot Chinese ADRs Gained in Morning Trading
  Alibaba, JD.com, Pinduoduo, Baidu, RLX Technology, IQiyi, Bilibili climbed between 2% and 8%.
  Hot Chinese ADRs Gained in Morning Trading
  2.37K Comment
  4
  Share
  Report
- anglizangliz
  ·2022-01-12
  🥳
  Why Alibaba And Other Tech Stocks Are Shooting Up In Hong Kong Today
  Shares of U.S.-listed Chinese tech companies surged in Hong Kong on Wednesday, leading the benchmark
  Why Alibaba And Other Tech Stocks Are Shooting Up In Hong Kong Today
  2.25K Comment
  6
  Share
  Report
- anglizangliz
  ·2022-01-09
  How many doses do we have to take eventually?🤪
  3 COVID Stocks That Will Make Billions in 2022
  These three COVID-19 stocks could rake in a tremendous amount of cash this year.
  3 COVID Stocks That Will Make Billions in 2022
  3.72K Comment
  7
  Share
  Report
- anglizangliz
  ·2021-09-23
  $CapitaLandInves(9CI.SI)$Went up for the past few days
  2.53K Comment
  2
  Share
  Report
- anglizangliz
  ·2021-09-23
  $THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$CGS-CIMB keeps 'add' on ThaiBev on attractive valuation.Link below:https://www.theedgesingapore.com/capital/brokers-calls/cgs-cimb-keeps-add-thaibev-attractive-valuation
  2.42K Comment
  1
  Share
  Report
- anglizangliz
  ·2021-09-22
  $HONG LEONG ASIA LTD.(H22.SI)$I am expecting this share to be around $1.
  2.36K Comment
  3
  Share
  Report
- anglizangliz
  ·2021-09-22
  $THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$Be patience.
  2.11K 1
  3
  Share
  Report
No followers yet

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3581117504935343","uuid":"3581117504935343","gmtCreate":1618148430364,"gmtModify":1706620740447,"name":"angliz","pinyin":"angliz","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":95,"headSize":430,"tweetSize":179,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.12%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9051023287,"gmtCreate":1654611383749,"gmtModify":1676535477923,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"Go go go!","listText":"Go go go!","text":"Go go go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9051023287","repostId":"1128523151","repostType":2,"repost":{"id":"1128523151","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1654609740,"share":"https://ttm.financial/m/news/1128523151?lang=&edition=fundamental","pubTime":"2022-06-07 21:49","market":"us","language":"en","title":"Some Hot Chinese ADRs Gained in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1128523151","media":"Tiger Newspress","summary":"Some Hot Chinese ADRs Gained in Morning Trading.Alibaba, Pinduoduo, iQIYI, DiDi Global, Baidu, JD.co","content":"<html><head></head><body><p>Some Hot Chinese ADRs Gained in Morning Trading.</p><p><a href=\"https://laohu8.com/S/BABA\">Alibaba</a>, <a href=\"https://laohu8.com/S/PDD\">Pinduoduo</a>, iQIYI, DiDi Global, <a href=\"https://laohu8.com/S/BIDU\">Baidu</a>, <a href=\"https://laohu8.com/S/JD\">JD.com</a>, Bilibili, and NIO climbed between 1% and 7%.</p><p><img src=\"https://static.tigerbbs.com/46cf305cfd9d3f235469219b4a219ad7\" tg-width=\"445\" tg-height=\"647\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Hot Chinese ADRs Gained in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Hot Chinese ADRs Gained in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-06-07 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some Hot Chinese ADRs Gained in Morning Trading.</p><p><a href=\"https://laohu8.com/S/BABA\">Alibaba</a>, <a href=\"https://laohu8.com/S/PDD\">Pinduoduo</a>, iQIYI, DiDi Global, <a href=\"https://laohu8.com/S/BIDU\">Baidu</a>, <a href=\"https://laohu8.com/S/JD\">JD.com</a>, Bilibili, and NIO climbed between 1% and 7%.</p><p><img src=\"https://static.tigerbbs.com/46cf305cfd9d3f235469219b4a219ad7\" tg-width=\"445\" tg-height=\"647\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1095":"互动媒体与服务","BILI":"哔哩哔哩","BK1591":"就地过年概念","BK4503":"景林资产持仓","BK4122":"互联网与直销零售","09988":"阿里巴巴-W","BK4502":"阿里概念","09618":"京东集团-SW","BK1521":"挪威政府全球养老基金持仓","PDD":"拼多多","BABA":"阿里巴巴","BK1586":"云计算","BK4577":"网络游戏","BK4510":"在线教育","09888":"百度集团-SW","BK4579":"人工智能","BIDU":"百度","BK4552":"Archegos爆仓风波概念","BK1142":"互联网与直销零售","BK4551":"寇图资本持仓","JD":"京东"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128523151","content_text":"Some Hot Chinese ADRs Gained in Morning Trading.Alibaba, Pinduoduo, iQIYI, DiDi Global, Baidu, JD.com, Bilibili, and NIO climbed between 1% and 7%.","news_type":1,"symbols_score_info":{"09888":0.9,"BABA":0.9,"09988":0.9,"BILI":0.9,"09618":0.9,"JD":0.9,"BIDU":0.9,"PDD":0.9}},"isVote":1,"tweetType":1,"viewCount":2971,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9059990241,"gmtCreate":1654272962983,"gmtModify":1676535423684,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Just bought abit of this share today! Huat ah!","listText":"<a href=\"https://ttm.financial/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Just bought abit of this share today! Huat ah!","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$Just bought abit of this share today! Huat ah!","images":[{"img":"https://community-static.tradeup.com/news/be2d3c77e2bf92d52c4e7bdab6f2bafe","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9059990241","isVote":1,"tweetType":1,"viewCount":2729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9099849467,"gmtCreate":1643334461026,"gmtModify":1676533806783,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"Wowed","listText":"Wowed","text":"Wowed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9099849467","repostId":"1110430857","repostType":4,"repost":{"id":"1110430857","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1643329098,"share":"https://ttm.financial/m/news/1110430857?lang=&edition=fundamental","pubTime":"2022-01-28 08:18","market":"us","language":"en","title":"Apple's Q1 Results A 'Major Statement Of iPhone/Services Demand': Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1110430857","media":"Benzinga","summary":"Apple, Inc. reported late Thursday with strong quarterly results that \"wowed\" a Wedbush analyst.The ","content":"<html><head></head><body><p><b>Apple, Inc.</b> reported late Thursday with strong quarterly results that &#34;wowed&#34; a Wedbush analyst.</p><p><img src=\"https://static.tigerbbs.com/46f1d5c88a1b989ac1e46cf46560b032\" tg-width=\"660\" tg-height=\"300\" width=\"100%\" height=\"auto\"/></p><p><b>The Apple Analyst:</b>Daniel Ives has an Outperform rating on Apple with a $200 price target.</p><p><b>The Apple Takeaways:</b>Apple&#39;s robust quarter will be the focus of the tech universe, especially as the Street harbored major supply chain and growth fears, heading into the print, Ives said in a note.</p><p>The iPhone was the &#34;star of the show,&#34; as revenues from the product beat the Street estimates and the Services business also exceeded expectations, the analyst said. The beat was across all product categories, except the iPad, he said.</p><p>The bottom-line result of $2.10 and margins were also ahead of expectations, Ives said.</p><p>&#34;Overall, with $6 billion already pushed due to the supply chain in the quarter, we would characterize this quarter as a major statement on iPhone/Services demand and Cupertino&#39;s ability to navigate a supply chain shortage in almost Teflon-like fashion,&#34; the analyst said.</p><p>Apple CEO <b>Tim Cook</b> noted supply chain improvement for the March quarter, which are &#34;calming words heard around the tech world,&#34; he said.</p><p>With ASPs continuing to be very positive on Pro/Pro Max and roughly 250 million of 975 million iPhones worldwide not upgrading in 3 1/2 years, the focus is on the demand front, Ives said. Supply chain issues are unlikely to crash the iPhone growth story in 2022, he said.</p><p><b>AAPL Price Action:</b>In after-hours trading, Apple shares were rallying 4.4% to $166.15.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple's Q1 Results A 'Major Statement Of iPhone/Services Demand': Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple's Q1 Results A 'Major Statement Of iPhone/Services Demand': Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-01-28 08:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><b>Apple, Inc.</b> reported late Thursday with strong quarterly results that &#34;wowed&#34; a Wedbush analyst.</p><p><img src=\"https://static.tigerbbs.com/46f1d5c88a1b989ac1e46cf46560b032\" tg-width=\"660\" tg-height=\"300\" width=\"100%\" height=\"auto\"/></p><p><b>The Apple Analyst:</b>Daniel Ives has an Outperform rating on Apple with a $200 price target.</p><p><b>The Apple Takeaways:</b>Apple&#39;s robust quarter will be the focus of the tech universe, especially as the Street harbored major supply chain and growth fears, heading into the print, Ives said in a note.</p><p>The iPhone was the &#34;star of the show,&#34; as revenues from the product beat the Street estimates and the Services business also exceeded expectations, the analyst said. The beat was across all product categories, except the iPad, he said.</p><p>The bottom-line result of $2.10 and margins were also ahead of expectations, Ives said.</p><p>&#34;Overall, with $6 billion already pushed due to the supply chain in the quarter, we would characterize this quarter as a major statement on iPhone/Services demand and Cupertino&#39;s ability to navigate a supply chain shortage in almost Teflon-like fashion,&#34; the analyst said.</p><p>Apple CEO <b>Tim Cook</b> noted supply chain improvement for the March quarter, which are &#34;calming words heard around the tech world,&#34; he said.</p><p>With ASPs continuing to be very positive on Pro/Pro Max and roughly 250 million of 975 million iPhones worldwide not upgrading in 3 1/2 years, the focus is on the demand front, Ives said. Supply chain issues are unlikely to crash the iPhone growth story in 2022, he said.</p><p><b>AAPL Price Action:</b>In after-hours trading, Apple shares were rallying 4.4% to $166.15.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110430857","content_text":"Apple, Inc. reported late Thursday with strong quarterly results that \"wowed\" a Wedbush analyst.The Apple Analyst:Daniel Ives has an Outperform rating on Apple with a $200 price target.The Apple Takeaways:Apple's robust quarter will be the focus of the tech universe, especially as the Street harbored major supply chain and growth fears, heading into the print, Ives said in a note.The iPhone was the \"star of the show,\" as revenues from the product beat the Street estimates and the Services business also exceeded expectations, the analyst said. The beat was across all product categories, except the iPad, he said.The bottom-line result of $2.10 and margins were also ahead of expectations, Ives said.\"Overall, with $6 billion already pushed due to the supply chain in the quarter, we would characterize this quarter as a major statement on iPhone/Services demand and Cupertino's ability to navigate a supply chain shortage in almost Teflon-like fashion,\" the analyst said.Apple CEO Tim Cook noted supply chain improvement for the March quarter, which are \"calming words heard around the tech world,\" he said.With ASPs continuing to be very positive on Pro/Pro Max and roughly 250 million of 975 million iPhones worldwide not upgrading in 3 1/2 years, the focus is on the demand front, Ives said. Supply chain issues are unlikely to crash the iPhone growth story in 2022, he said.AAPL Price Action:In after-hours trading, Apple shares were rallying 4.4% to $166.15.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":2496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9007057283,"gmtCreate":1642725378260,"gmtModify":1676533740180,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"Horray!","listText":"Horray!","text":"Horray!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9007057283","repostId":"1134491773","repostType":2,"repost":{"id":"1134491773","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642689793,"share":"https://ttm.financial/m/news/1134491773?lang=&edition=fundamental","pubTime":"2022-01-20 22:43","market":"us","language":"en","title":"Hot Chinese ADRs Gained in Morning Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1134491773","media":"Tiger Newspress","summary":"Alibaba, JD.com, Pinduoduo, Baidu, RLX Technology, IQiyi, Bilibili climbed between 2% and 8%.","content":"<html><head></head><body><p>Alibaba, JD.com, Pinduoduo, Baidu, RLX Technology, IQiyi, Bilibili climbed between 2% and 8%.</p><p><img src=\"https://static.tigerbbs.com/96bc8b16c942e17e728eded527960910\" tg-width=\"405\" tg-height=\"588\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot Chinese ADRs Gained in Morning Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot Chinese ADRs Gained in Morning Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-20 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Alibaba, JD.com, Pinduoduo, Baidu, RLX Technology, IQiyi, Bilibili climbed between 2% and 8%.</p><p><img src=\"https://static.tigerbbs.com/96bc8b16c942e17e728eded527960910\" tg-width=\"405\" tg-height=\"588\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PDD":"拼多多","JD":"京东"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134491773","content_text":"Alibaba, JD.com, Pinduoduo, Baidu, RLX Technology, IQiyi, Bilibili climbed between 2% and 8%.","news_type":1,"symbols_score_info":{"PDD":0.9,"JD":0.9}},"isVote":1,"tweetType":1,"viewCount":2368,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002822441,"gmtCreate":1641969751391,"gmtModify":1676533667690,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"🥳","listText":"🥳","text":"🥳","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002822441","repostId":"1169397242","repostType":4,"repost":{"id":"1169397242","kind":"news","pubTimestamp":1641965030,"share":"https://ttm.financial/m/news/1169397242?lang=&edition=fundamental","pubTime":"2022-01-12 13:23","market":"us","language":"en","title":"Why Alibaba And Other Tech Stocks Are Shooting Up In Hong Kong Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1169397242","media":"Benzinga","summary":"Shares of U.S.-listed Chinese tech companies surged in Hong Kong on Wednesday, leading the benchmark","content":"<div>\n<p>Shares of U.S.-listed Chinese tech companies surged in Hong Kong on Wednesday, leading the benchmark Hang Seng Index notably higher.What’s Moving: Shares of Alibaba Group Holding Limited,BaiduInc.,JD....</p>\n\n<a href=\"https://www.benzinga.com/news/22/01/25010161/why-alibaba-and-other-tech-stocks-are-shooting-up-in-hong-kong-today\">Web Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Alibaba And Other Tech Stocks Are Shooting Up In Hong Kong Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Alibaba And Other Tech Stocks Are Shooting Up In Hong Kong Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-12 13:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/22/01/25010161/why-alibaba-and-other-tech-stocks-are-shooting-up-in-hong-kong-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of U.S.-listed Chinese tech companies surged in Hong Kong on Wednesday, leading the benchmark Hang Seng Index notably higher.What’s Moving: Shares of Alibaba Group Holding Limited,BaiduInc.,JD....</p>\n\n<a href=\"https://www.benzinga.com/news/22/01/25010161/why-alibaba-and-other-tech-stocks-are-shooting-up-in-hong-kong-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09988":"阿里巴巴-W"},"source_url":"https://www.benzinga.com/news/22/01/25010161/why-alibaba-and-other-tech-stocks-are-shooting-up-in-hong-kong-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169397242","content_text":"Shares of U.S.-listed Chinese tech companies surged in Hong Kong on Wednesday, leading the benchmark Hang Seng Index notably higher.What’s Moving: Shares of Alibaba Group Holding Limited,BaiduInc.,JD.Com Inc., Tencent Holdings Inc., Li Auto Inc. and Xpeng Inc., traded higher in a range of 3% to 9%.The Hang Seng Index rebounded opened higher on Wednesday and was up almost 2.0% at the time of writing. The index closed little changed on Tuesday, ending a three-day winning streak.Why Is It Moving? The Hang Seng Index rose after official data showed that China’s inflation rose slower than expected in December. The data raised hopes of more policy easing as China’s economy continues to struggle with property sector woes and repeated COVID-19 outbreaks.China’s consumer price Index (CPI) grew 1.5% year-over-year in December, while the producer price index (PPI) rose 10.3% from a year earlier, as per areport by Reuters, citing the National Bureau of Statistics.Tesla Inc.’s China sales rose in December and outperformed the industry in terms of year-over-year and sequential growth, it was reported on Tuesday. The Elon Musk-led company’s Chinese rivals —Nio Inc., XPeng and Li Auto — had also previously reported strong deliveries for December.Shares of Chinese companies closed notably higher in U.S. trading on Monday after the major averages in the U.S. ended higher. Federal Reserve Chair Jerome Powell said the central bank would use all of its tools to prevent higher inflation from becoming entrenched.Alibaba’s shares closed 3.0% higher, while Nio’s shares ended higher by 3.8%.","news_type":1,"symbols_score_info":{"09988":0.9}},"isVote":1,"tweetType":1,"viewCount":2250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006879908,"gmtCreate":1641695723593,"gmtModify":1676533640723,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"How many doses do we have to take eventually?🤪","listText":"How many doses do we have to take eventually?🤪","text":"How many doses do we have to take eventually?🤪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006879908","repostId":"1134509683","repostType":4,"repost":{"id":"1134509683","kind":"news","pubTimestamp":1641612579,"share":"https://ttm.financial/m/news/1134509683?lang=&edition=fundamental","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<html><head></head><body><p>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><b>A safe harbor in stormy weather</b></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><b>Revenue forecasts for Novavax:  $2 billion to $8 billion</b></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.</p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.</p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><b>The antibody market all to itself</b></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.</p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-08 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","VIR":"Vir Biotechnology, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax:  $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1,"symbols_score_info":{"VIR":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3718,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3574671931921507","authorId":"3574671931921507","name":"Wayneqq","avatar":"https://static.tigerbbs.com/05d24be2c05653913e90f51e69cfe2a8","crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3574671931921507","idStr":"3574671931921507"},"content":"Until the next virus comes along to render it totally ineffective.. i predict it will be an annual affair or biannual.. similar to flu shots","text":"Until the next virus comes along to render it totally ineffective.. i predict it will be an annual affair or biannual.. similar to flu shots","html":"Until the next virus comes along to render it totally ineffective.. i predict it will be an annual affair or biannual.. similar to flu shots"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863557941,"gmtCreate":1632407875483,"gmtModify":1676530775733,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/9CI.SI\">$CapitaLandInves(9CI.SI)$</a>Went up for the past few days","listText":"<a href=\"https://laohu8.com/S/9CI.SI\">$CapitaLandInves(9CI.SI)$</a>Went up for the past few days","text":"$CapitaLandInves(9CI.SI)$Went up for the past few days","images":[{"img":"https://static.tigerbbs.com/97150f41d6ac3fb70544cd1131cb3f9f","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863557941","isVote":1,"tweetType":1,"viewCount":2532,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":863552125,"gmtCreate":1632407738367,"gmtModify":1676530775660,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>CGS-CIMB keeps 'add' on ThaiBev on attractive valuation.Link below:https://www.theedgesingapore.com/capital/brokers-calls/cgs-cimb-keeps-add-thaibev-attractive-valuation","listText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>CGS-CIMB keeps 'add' on ThaiBev on attractive valuation.Link below:https://www.theedgesingapore.com/capital/brokers-calls/cgs-cimb-keeps-add-thaibev-attractive-valuation","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$CGS-CIMB keeps 'add' on ThaiBev on attractive valuation.Link below:https://www.theedgesingapore.com/capital/brokers-calls/cgs-cimb-keeps-add-thaibev-attractive-valuation","images":[{"img":"https://static.tigerbbs.com/8789742cb331f1363cd7ad21804169bd","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863552125","isVote":1,"tweetType":1,"viewCount":2419,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":869630433,"gmtCreate":1632277767622,"gmtModify":1676530741756,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/H22.SI\">$HONG LEONG ASIA LTD.(H22.SI)$</a>I am expecting this share to be around $1.","listText":"<a href=\"https://laohu8.com/S/H22.SI\">$HONG LEONG ASIA LTD.(H22.SI)$</a>I am expecting this share to be around $1.","text":"$HONG LEONG ASIA LTD.(H22.SI)$I am expecting this share to be around $1.","images":[{"img":"https://static.tigerbbs.com/ef5ade7f3180f3e0f369e9e2a0d98c1a","width":"1080","height":"3075"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869630433","isVote":1,"tweetType":1,"viewCount":2358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":869630635,"gmtCreate":1632277707527,"gmtModify":1676530741757,"author":{"id":"3581117504935343","authorId":"3581117504935343","name":"angliz","avatar":"https://static.tigerbbs.com/597bdbc34d024b3a2ce151e72698ccb4","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581117504935343","idStr":"3581117504935343"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Be patience.","listText":"<a href=\"https://laohu8.com/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>Be patience.","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$Be patience.","images":[{"img":"https://static.tigerbbs.com/e609987ca7b55f9120f8751d34eee260","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869630635","isVote":1,"tweetType":1,"viewCount":2108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":true}